Reported Earnings • May 17
Second quarter 2026 earnings released: CA$0.01 loss per share (vs CA$0 in 2Q 2025) Second quarter 2026 results: CA$0.01 loss per share (further deteriorated from CA$0 in 2Q 2025). Revenue: CA$3.38m (down 37% from 2Q 2025). Net loss: CA$1.43m (down CA$1.45m from profit in 2Q 2025). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 63% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. New Risk • May 15
New major risk - Revenue and earnings growth Earnings have declined by 3.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (CA$31.7m market cap, or US$23.0m). Tillkännagivande • May 07
Microbix Biosystems Inc. to Report Q2, 2026 Results on May 14, 2026 Microbix Biosystems Inc. announced that they will report Q2, 2026 results Pre-Market on May 14, 2026 Reported Earnings • Feb 13
First quarter 2026 earnings released: CA$0.008 loss per share (vs CA$0.006 profit in 1Q 2025) First quarter 2026 results: CA$0.008 loss per share (down from CA$0.006 profit in 1Q 2025). Revenue: CA$4.22m (down 30% from 1Q 2025). Net loss: CA$1.17m (down 236% from profit in 1Q 2025). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 70% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 16% per year. Tillkännagivande • Feb 05
Microbix Biosystems Inc. to Report Q1, 2026 Results on Feb 12, 2026 Microbix Biosystems Inc. announced that they will report Q1, 2026 results Pre-Market on Feb 12, 2026 Tillkännagivande • Jan 14
Microbix Biosystems Inc., Annual General Meeting, Mar 25, 2026 Microbix Biosystems Inc., Annual General Meeting, Mar 25, 2026. Tillkännagivande • Jan 07
Microbix Commercializes Sars-Cov-2 (Covid) Recombinant Antigen for Usage in Qaps and Test Manufacturing Microbix Biosystems Inc. announced the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products ("QAPs™?") and its availability at commercial scale for test manufacturers. This is the first commercial product to emerge from the development program announced in January 2025, whereby Microbix committed to extend its capabilities into recombinant (i.e., synthetic) antigen production to complement its longstanding expertise in native antigen production. This internally-made recombinant antigen has been developed, manufactured at commercial scale, and fully validated. Accordingly, it is now being used in Microbix's QAPs to support clinical laboratory proficiency testing or external quality assessment programs ("PT" or "EQA"), and is being incorporated into PROCEEDx®? (RUO) and REDx®? (IVD) branded QAPs used to support ongoing quality management of clinical laboratories or other testing sites. Microbix has 40 years of expertise in the technically-challenging manufacturing of native viral antigens, which requires culturing of mammalian host cells, the addition and growth of target viruses in those cells, and, finally, the extraction, purification, and inactivation of high-quality components for infectious-disease tests in commercial quantities. Reported Earnings • Dec 18
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: CA$0.016 loss per share (down from CA$0.026 profit in FY 2024). Revenue: CA$18.6m (down 27% from FY 2024). Net loss: CA$2.25m (down 164% from profit in FY 2024). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 73% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Tillkännagivande • Dec 12
Microbix Biosystems Inc. to Report Q4, 2025 Results on Dec 18, 2025 Microbix Biosystems Inc. announced that they will report Q4, 2025 results Pre-Market on Dec 18, 2025 Tillkännagivande • Dec 11
Microbix Biosystems Inc. Launches New Products to Support H3N2 Flu Testing Microbix Biosystems Inc. announced the commercial launch of QAPs™? quality assessment products and availability of QUANTDx™? reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the "Flu"). H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to "antigenic drift," changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection natural immunity and vaccine-induced immunity normally provide. Specifically, Microbix's Respiratory QAPs formulated with H3N2 can be used as safe, reliable, and stable molecularetics of patient-samples for training of persons administering tests, validation of new testing sites, and verification of instrument/assay performance. Depending on the nature of their needs, users can select either PROCEEDx®? (RUO) or REDx®? (IVD) variants of these QAPs. Upon request, H3N2 reference materials can also be made available, as part of Microbix's QUANTDx product-line. QUANTDx products are well-characterized, accurately-quantified and fully-traceable reference materials that enable assay developers to establish key analytical performance metrics - such as LoD (limit of detection), Sens sensitivity (positive accuracy), and Specificity (negative accuracy) - knowledge that is essential for validation and regulatory submissions. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic®? urokinase, a biologic thrombolytic drug used to treat blood clots, and agents to support diagnostic testing (e.g., its DxTM™? for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Reported Earnings • Aug 14
Third quarter 2025 earnings released: CA$0.012 loss per share (vs CA$0.002 profit in 3Q 2024) Third quarter 2025 results: CA$0.012 loss per share (down from CA$0.002 profit in 3Q 2024). Revenue: CA$3.47m (down 31% from 3Q 2024). Net loss: CA$1.64m (down CA$1.89m from profit in 3Q 2024). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 65% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 07
Microbix Biosystems Inc. to Report Q3, 2025 Results on Aug 14, 2025 Microbix Biosystems Inc. announced that they will report Q3, 2025 results Pre-Market on Aug 14, 2025 New Risk • Jun 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 106% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (6.9% net profit margin). Market cap is less than US$100m (CA$84.5m market cap, or US$61.8m). Reported Earnings • May 15
Second quarter 2025 earnings released: EPS: CA$0 (vs CA$0.003 in 2Q 2024) Second quarter 2025 results: EPS: CA$0 (down from CA$0.003 in 2Q 2024). Revenue: CA$5.32m (down 5.5% from 2Q 2024). Net income: CA$20.7k (down 95% from 2Q 2024). Profit margin: 0.4% (down from 6.7% in 2Q 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 62% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Tillkännagivande • May 08
Microbix Biosystems Inc. to Report Q2, 2025 Results on May 15, 2025 Microbix Biosystems Inc. announced that they will report Q2, 2025 results Pre-Market on May 15, 2025 New Risk • Apr 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 106% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (8.3% net profit margin). Significant insider selling over the past 3 months (CA$159k sold). Market cap is less than US$100m (CA$99.1m market cap, or US$71.3m). Price Target Changed • Apr 10
Price target decreased by 11% to CA$0.80 Down from CA$0.90, the current price target is provided by 1 analyst. New target price is 129% above last closing price of CA$0.35. Stock is down 2.8% over the past year. The company is forecast to post earnings per share of CA$0.01 for next year compared to CA$0.026 last year. Reported Earnings • Feb 14
First quarter 2025 earnings released: EPS: CA$0.006 (vs CA$0.018 in 1Q 2024) First quarter 2025 results: EPS: CA$0.006 (down from CA$0.018 in 1Q 2024). Revenue: CA$6.04m (down 28% from 1Q 2024). Net income: CA$857.0k (down 65% from 1Q 2024). Profit margin: 14% (down from 29% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 64% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 06
Microbix Biosystems Inc. to Report Q1, 2025 Results on Feb 13, 2025 Microbix Biosystems Inc. announced that they will report Q1, 2025 results After-Market on Feb 13, 2025 Recent Insider Transactions Derivative • Jan 24
Independent Director exercised options to buy CA$182k worth of stock. On the 22nd of January, Peter Blecher exercised options to buy 375k shares at a strike price of around CA$0.36, costing a total of CA$135k. This transaction amounted to 13% of their direct individual holding at the time of the trade. Since March 2024, Peter's direct individual holding has increased from 2.81m shares to 2.94m. Company insiders have collectively bought CA$301k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions • Jan 24
President recently sold CA$95k worth of stock On the 22nd of January, Cameron Groome sold around 220k shares on-market at roughly CA$0.43 per share. This transaction amounted to 6.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Cameron has been a net seller over the last 12 months, reducing personal holdings by CA$215k. Tillkännagivande • Jan 15
Microbix Biosystems Inc., Annual General Meeting, Mar 26, 2025 Microbix Biosystems Inc., Annual General Meeting, Mar 26, 2025. Tillkännagivande • Jan 14
Microbix Biosystems Inc. and American Proficiency Institute Announce the Start of Pilot Pt Program to Ensure That Molecular Diagnostic Assays Microbix Biosystems Inc. and American Proficiency Institute announced the start of a pilot PT program to ensure that molecular diagnostic assays can detect the emerging H5N1 strain of the Influenza A virus (“H5N1 Flu”). Strains of the Flu are named according to variations in the proteins that help them to infect host cells – the Hemagglutinin protein and the Neuraminidase protein. There is a heightened risk of a pandemic when one or both of the H or N proteins have not been circulating in human populations. H5N1 is such a relatively novel strain of the Flu virus, which has demonstrated the ability to infect birds, cattle, and humans. H5N1 Flu is now circulating on multiple continents and may become a new pandemic, with it having demonstrated a staggering rate of severe pneumonia and death across those infected thus far. It is therefore critical to prove whether established MDx tests can accurately and reliably detect H5N1 Flu. Such MDx Flu tests include both regulator-approved assays and laboratory-developed tests, respectively classed as “IVD” and “LDT”. Clinical labs must objectively prove that every such assay they are using can reliably detect H5N1 Flu requiring novel quality assessment products and new PT programs. Microbix and API have been collaborating to fulfill this critical and urgent need. Using its virology and synthetic biology expertise, Microbix has created a novel QAP that provides the whole genome of H5N1 Flu, but which does not require use of nor contain any infectious materials. In turn, API is initiating a proficiency testing program whereby clinical labs can independently confirm their MDx assays and the established workflows in use will reliably detect H5N1 Flu. This pilot PT program is now live, and API will invite a limited number of labs to participate before such a program is offered to all API clients. Recent Insider Transactions Derivative • Jan 10
Insider exercised options to buy CA$84k worth of stock. On the 6th of January, Mark Luscher exercised options to buy 200k shares at a strike price of around CA$0.29, costing a total of CA$58k. This transaction amounted to 54% of their direct individual holding at the time of the trade. Since March 2024, Mark's direct individual holding has increased from 369.67k shares to 569.67k. Company insiders have collectively bought CA$231k more than they sold, via options and on-market transactions, in the last 12 months. Tillkännagivande • Jan 08
Microbix Biosystems Inc. Announces its Intentions to Broaden its Platform Capabilities to Enable Production of Wide Range of Test Ingredients (Antigens) by Using Recombinant Production Technologies Microbix Biosystems Inc. announced its intentions to broaden its platform capabilities to enable production of a wide range of test ingredients (Antigens) by using recombinant production technologies. Directing existing in-house synthetic biology capabilities to this project will create large-scale recombinant Antigens production to complement and expand Microbix’s addressable market share as a key supplier to manufacturers of immunoassays – the class of diagnostic tests that establishes exposure to, or immunity from, pathogens. Microbix has been a leading producer of purified and inactivated Antigens from native (natural) bacterial and viral organisms for more than three decades. It supplies these critical biological ingredients to more than 100 international manufacturers of immunoassays where test accuracy is maximized by using such Antigens. Microbix’s sales of native Antigens totaled CAD 13.8 million in fiscal 2024, an increase of 44% from the prior year and generated from a catalogue of dozens of these complex and valuable biomaterials. However, to date Microbix has not broadly participated in making Antigens using the recombination of genetic materials from different species (i.e., recombinant technologies). Such recombinant Antigens can have price advantages relative to native Antigens and are the choice of immunoassay makers in situations where they can be used without sacrificing assay performance. Microbix offering recombinant Antigens will increase the extent to which it can grow sales of this important segment of its business. Microbix has therefore decided to fund the augmentation of its internal capabilities in synthetic biology in order to build the processes and capacity for production of recombinant Antigens. This will entail adding trained staff, equipment, biological vectors, and cell-lines. With the infrastructure and capabilities already built-out over the past several years, the incremental investment needed to drive the opening of these new market opportunities will be modest, at about CAD 0.5 million per year. Buy Or Sell Opportunity • Dec 30
Now 20% undervalued Over the last 90 days, the stock has risen 19% to CA$0.41. The fair value is estimated to be CA$0.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.6% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Dec 20
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: CA$0.026 (up from CA$0 in FY 2023). Revenue: CA$25.4m (up 54% from FY 2023). Net income: CA$3.52m (up CA$3.56m from FY 2023). Profit margin: 14% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 30%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 55% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Dec 19
Microbix Biosystems Inc. Provides Financial Guidance for the Full-Year of Fiscal 2025 Microbix Biosystems Inc. provides financial guidance for the full-year of fiscal 2025. For the period, the company will continue driving sales growth across all of its business lines, while working to keep improving percentage gross margins, and delivering bottom-line results. The company currently expects to generate meaningful year-over-year growth in revenues. Tillkännagivande • Dec 12
Microbix Biosystems Inc. to Report Q4, 2024 Results on Dec 19, 2024 Microbix Biosystems Inc. announced that they will report Q4, 2024 results Pre-Market on Dec 19, 2024 Tillkännagivande • Nov 12
KOL Collaborators Present Microbix HPV Test-Control Results Microbix Biosystems Inc. announced that key opinion leader collaborators are presenting results of a Microbix Quality Assessment Product (“QAP”) for controlling testing for high-risk types of Human Papilloma Virus at the 36th annual International Papillomavirus Conference (“IPVC”) taking place in Edinburgh, Scotland, November 12 to 15, 2024. IPVC is the annual conference of the International Papillomavirus Society (“IVPS”), a not-for-profit organization of biomedical scientists investigating human and animal papillomaviruses and their associated diseases. IPVS is the global authority on papillomaviruses and its mission is to contribute to the elimination of papillomavirus-related diseases. HPV is best known as the undisputed cause of cervical cancer in women, driven by long-term infection with one or more high-risk types of the virus family. When properly validated and controlled, molecular (e.g., PCR-based) testing for HPV infection enables cervical cancer screening programs to identify at-risk patients years before the development of invasive cancer. Furthermore, cervical cancer screening programs can increase participation rates by enabling women to “self-collect” samples in the privacy of their homes, rather than remaining reliant on whether every at-risk women has ready access to medical professionals to collect their samples. At IPVC, authors Willem Ford, Marco Ho Ting Keung, and David Hawkes will present their poster titled “Validation of Commercial FLOQSwab® Quality Control for Human papillomavirus detection on six ISO 15189 accredited self-collection methods.” Their aim was to examine the compatibility of Microbix’s PROCEEDx®FLOQ® (HPV 16/18/45) QAP (RUO) to support testing for the three most common high-risk types of HPV and assess its viability as a quality control (“QC”) product. Their work tested use of this Microbix QAP with two commonly-used liquid media and six commercial and clinically-validated HPV assays. The results indicate that this QAP could be used for effective estimation of sensitivity, specificity, and both negative and positive predictive values with different self-collection methods and has a 100% concordance with detection across the two media types and for all six HPV assays. The authors concluded that the PROCEEDxFLOQ (HPV 16/18/45) “has excellent analytical performance and provides a QC product for use by laboratories processing self-collection using methods involving the Copan FLOQSwab''. Microbix thanks Professor David Hawkes, the Australian Centre for the Prevention of Cervical Cancer, the University of Melbourne (Australia), and the University of Malaya (Malaysia) for conducting this work. Recent Insider Transactions • Oct 15
President recently sold CA$73k worth of stock On the 9th of October, Cameron Groome sold around 220k shares on-market at roughly CA$0.33 per share. This transaction amounted to 7.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Cameron has been a net seller over the last 12 months, reducing personal holdings by CA$120k. Tillkännagivande • Oct 07
Microbix Biosystems Inc. to Present Results of Novel Quality Assessment Product At the European Meeting on Molecular Diagnostics Microbix Biosystems Inc. announced that it is presenting results of a novel Quality Assessment Product ("QAPTM") for supporting patient diagnosis and tissue analysis relating to infection with the Herpes Simplex Virus ("HSV") at the European Meeting on Molecular Diagnostics ("EMMD") taking place in Noordwijk, The Netherlands, October 9 to 11, 2024. At EMMD, Microbix will interact with key opinion leaders, collaborators, and customers that create and utilize the available assays to diagnose, screen, and direct treatment of HSV, many other infectious diseases, and other conditions such as cancers. Microbix will also be attending multiple scientific and clinical care lectures and discussions that are directly pertinent to its ever-growing portfolio of QAPs that help ensure the accuracy of molecular (i.e., "PCR") tests and their workflows. Also at EMMD, Microbix will present its poster titled "FFPE HSV-1 and HSV-2 simulated tissue sections mounted on slides for use as prospective quality controls in IHC and qPCR workflows." The poster reviews the performance of a novel (RUO) QAP to support PCR-based detection of HSV and immunohistochemical analysis of Formalin-Fixed and Paraffin-Embedded ("FFPE") tissue samples. Following presentation of the poster on the afternoon of October 9th, it will be made available at https://microbix.com. In spite of efforts to detect, treat, and prevent the spread of HSV, it is estimated that over half of all people worldwide are chronically infected with a strain of this virus. Emerging research is also establishing that chronic infection with HSV is a risk factor for, and can lead to, severe conditions like esophagitis, hepatitis, pneumonia, encephalitis, cancer, and neurodegenerative disorders. More widespread diagnosis of HSV and detailed analysis of infected tissues may therefore be a route to prevention of the serious health consequences that can result from HSV infections. Microbix is pleased to support the more widespread use of such testing by helping to ensure its quality and accuracy. Reported Earnings • Aug 15
Third quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.006 loss in 3Q 2023) Third quarter 2024 results: EPS: CA$0.002 (up from CA$0.006 loss in 3Q 2023). Revenue: CA$5.06m (down 8.5% from 3Q 2023). Net income: CA$246.7k (up CA$1.02m from 3Q 2023). Profit margin: 4.9% (up from net loss in 3Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 61% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 07
Microbix Biosystems Inc. to Report Q3, 2024 Results on Aug 13, 2024 Microbix Biosystems Inc. announced that they will report Q3, 2024 results Pre-Market on Aug 13, 2024 Tillkännagivande • Jul 26
Microbix Biosystems Inc. Presents HCV FLOQSwab Format Test Control at ADLM Microbix Biosystems Inc. announced that it is presenting results of a novel Quality Assessment Product for supporting Point-of-Care-Tests for infection with the Hepatitis C Virus at the American Diagnostic and Laboratory Medicine conference taking place in Chicago, Illinois July 29 to August 1, 2024. At ADLM, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of HCV and many other infectious diseases. Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular tests and their workflows. Also at ADLM, Microbix'll present its poster titled "Novel Hepatitis C Virus External Quality Control that is Stable at Ambient Temperature and Suitable for Use in Low- Resource Settings." The poster reviews the performance of a novel PROCEED®?FLOQ®? (RUO) QAP to support the training for and prospective quality management of POCT PCR tests that use fingerstick whole-blood samples to detect HCV. In spite of efforts to eliminate viral hepatitis, it is estimated that 58 million individuals are infected with HCV. The majority of such persons live where conventional lab-based diagnostics are inaccessible due to high costs, want of equipment or trained personnel, or lack of “cold-chain” refrigeration. HCV POCTs are therefore critical for improving test accessibility, surveillance, and treatment, with such POCTs requiring suitably designed and robust External Quality Controls to monitor the accuracy of testing. The novel Microbix HCV QAP is formatted onto a COPAN® FLOQSwab® to help achieve a consistent and accurate signal, provide room-temperature stability, and be superior to conventional HCV quality controls that must be kept frozen until use. The QAP is also whole-genome to contain all relevant PCR-test targets, works with the relevant sample-elution reagents, and has long-term stability at ambient temperatures (i.e., 2 to 30 ºC). This QAP is intended to facilitate and accelerate the rollout and adoption of POCTs for HCV, particularly for geographically or culturally-isolated persons and in low or middle-income countries. Reported Earnings • May 17
Second quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0 in 2Q 2023) Second quarter 2024 results: EPS: CA$0.003 (up from CA$0 in 2Q 2023). Revenue: CA$5.63m (up 34% from 2Q 2023). Net income: CA$377.7k (up CA$346.1k from 2Q 2023). Profit margin: 6.7% (up from 0.7% in 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 78% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Tillkännagivande • May 10
Microbix Biosystems Inc. to Report Q2, 2024 Results on May 15, 2024 Microbix Biosystems Inc. announced that they will report Q2, 2024 results Pre-Market on May 15, 2024 Tillkännagivande • Mar 12
Microbix Biosystems Inc. Unveils Test Controls for Head and Neck Cancer Microbix Biosystems Inc. announced that it is presenting results of Quality Assessment Products ("QAPs") for supporting the quality control ("QC") of histology and PCR-based tests driven by tissue-s samples of Head and Neck cancer caused by human papilloma virus ("HPV"). Its results presentation will be made at EUROGIN 2024, an international collaborative conference and exhibition focused upon innovations in HPV research and global cancer solutions taking place in Stockholm, Sweden from March 13 to 16, 2024. While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues. Such further types of HPV-driven cancer include those of the "Head and Neck," collectively tumours inside and behind the nose, throughout the mouth (including the tongue, gums, and palate), all sections of the throat, and the voice box. Diagnosis of such cancers is made from tissue sample analyses that look for the presence of cancerous cells via histology and the presence of viral DNA by PCR. New Risk • Feb 25
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: CA$68k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (20% accrual ratio). Minor Risks Significant insider selling over the past 3 months (CA$68k sold). Market cap is less than US$100m (CA$54.9m market cap, or US$40.6m). Tillkännagivande • Feb 24
Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024 Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024, at 13:00 US Eastern Standard Time. Agenda: To consider receiving the 2023 annual report; To consider electing directors; To consider re-appointing Ernst & Young LLP; To consider and approve with or without amendment. Reported Earnings • Feb 16
First quarter 2024 earnings released: EPS: CA$0.018 (vs CA$0.009 loss in 1Q 2023) First quarter 2024 results: EPS: CA$0.018 (up from CA$0.009 loss in 1Q 2023). Revenue: CA$8.41m (up 236% from 1Q 2023). Net income: CA$2.46m (up CA$3.75m from 1Q 2023). Profit margin: 29% (up from net loss in 1Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 59% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 08
Microbix Biosystems Inc. to Report Q1, 2024 Results on Feb 14, 2024 Microbix Biosystems Inc. announced that they will report Q1, 2024 results Pre-Market on Feb 14, 2024 Tillkännagivande • Jan 13
Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024 Microbix Biosystems Inc., Annual General Meeting, Mar 27, 2024. Reported Earnings • Dec 22
Full year 2023 earnings: Revenues miss analyst expectations Full year 2023 results: Revenue: CA$16.5m (down 13% from FY 2022). Net loss: CA$39.5k (down 102% from profit in FY 2022). Revenue missed analyst estimates by 75%. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Tillkännagivande • Dec 22
Microbix Biosystems Inc. Provides Earnings Guidance for the Full-Year Fiscal 2024 Microbix Biosystems Inc. provided earnings guidance for the full-year fiscal 2024. The company expects to generate meaningful sales and net earnings growth across full-year fiscal 2024. Reported Earnings • Aug 11
Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.005 profit in 3Q 2022) Third quarter 2023 results: CA$0.006 loss per share (down from CA$0.005 profit in 3Q 2022). Revenue: CA$5.53m (up 10% from 3Q 2022). Net loss: CA$769.1k (down 221% from profit in 3Q 2022). Revenue is forecast to grow 59% p.a. on average during the next 2 years, compared to a 71% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Tillkännagivande • Aug 05
Microbix Successfully Upgrades Logistics Software Systems Achieves “Go-Live” with New ERP and eQMS Solutions Microbix Biosystems Inc. announces its successful adoption of software to upgrade, digitize, and integrate its Enterprise Resource Planning (“ERP”) platform and electronic Quality Management System (“eQMS”). These logistics IT systems are intended to facilitate growth in sales of Microbix’s product lines and thereby enable achievement of its business objectives. Microbix announced its selection of new ERP and eQMS systems in March, 2022, with its goal being to achieve “Go-Live” with each by the end of fiscal 2023 (i.e., September 30, 2023). That goal is now achieved, with the new ERP software supporting operations from raw materials procurement through to receivables collection. In turn, processes relating to product development, SKU manufacturing, QC/QA, and staff training are now being digitized via the new eQMS system. These logistics software upgrades are deemed essential for Microbix to realize its objective of driving sales toward CAD 100 million per year while maintaining optimal quality and pricing for its customers. NetSuite® is Microbix’s chosen ERP software, approaching 30,000 unique clients with over 1,000 in the Medtech/Pharma fields. This ERP integrates seamlessly with eQMS to provide a complete and scalable solution including manufacturing, QC/QA, finance, sales & CRM, inventory control, and compliance. MasterControl® is the chosen eQMS provider, having been a market leader for over 25 years, active in over 50 countries and with over 750 Medtech clients. Its eQMS fully-digitizes manufacturing batch-production-records, testing documentation, and training processes to increase throughput and reduce errors. Tillkännagivande • Jul 25
Microbix Biosystems Inc. Presents Results of STI Test Controls at AACC Microbix Biosystems Inc. announced that it is presenting results of its Quality Assessment Products (“QAPs™”) for supporting the clinical use and accuracy of multiplex tests for four of the most prevalent sexually-transmitted infections (“STIs”) at the American Association of Clinical Chemistry (“AACC”) conference taking place in Anaheim, CaliforniaJuly 23 to 27, 2023. At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases. Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows. Also at AACC, Microbix will present a poster titled “Evaluating the Performance of Emerging STI Point of Care Assays Using Novel, Room Temperature Stable CT/NG/TV/MG Positive Swab Quality Control Materials.” The poster reviews the performance of novel PROCEED®FLOQ® (RUO) QAPs to support the clinical use and accuracy of multiplex PCR tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) – four of the most prevalent STIs. Point of Care Tests (“PoCTs”) that can distinguish between STI-causing pathogens promise improved access to care and faster turnaround time from patient-sampling to test-result. However, users of such PoCTs must have accurate and robust test-control materials for quality management purposes. Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens. The poster evaluated its performance with multiple diagnostic platforms in current use and in development, namely the Abbott Alinity™ m STI assay, Aprimeo/Bosch Vivalytic™ STI Assay, BD MAX™ CT/GC/TV assay, Cepheid Xpert® CT/NG and TV assays, Seegene Novaplex™ CT/NG/TV/MG assay, an IVD assay in late-stage development, and a lab-developed assay. Tillkännagivande • Jun 14
Microbix Biosystems Inc. Presents Results of STI Test Controls at ASM Microbe Microbe FLOQ Microbix Biosystems Inc. announced that it is presenting results of its Quality Assessment Products ("QAPs™?") for supporting the clinical use and accuracy of tests for antimicrobial-resistant ("AMR") sexually-transmitted infections ("STIs") at the ASM Microbe conference of the American Society of Microbiology ("ASM"), taking place in Houston, Texas June 15-19, 2023. At ASM Microbe, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases. Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and nucleic acid (i.e., "PCR") tests and their workflows. Also at the conference Microbix will present a poster titled "Evaluating the Performance of Nucleic Acid Amplification Tests that Detect Mycoplasma genitalium and Mutations Associated with Macrolide Resistance Using Novel Quality Controls Formatted on Swabs." The poster reviews the performance of novel REDx FLOQ (IVD) and PROCEEDx™?FLOQ (RUO) ®? ®?. QAPs to support the clinical use and accuracy of test for AMR variants of the STI Mycoplasma genitalium ("Mgen"), a common cause of urethritis, cervicitis, pelvic inflammatory disease, and infertility. As is becoming increasingly common with many infections, the emergence of AMR variants of Mgen is leading to a high rate of first-line treatment failure (i.e., 44-90%). If accuracy can be ensured, PCR-based testing can greatly improve treatment outcomes, but quality-control materials to support such tests were largely unavailable. The resulting room-temperature stable QAPs demonstrate that they support testing with varied advanced PCR-assay workflows and elution buffers. Microbix is therefore pleased to be offering flocked-swab formatted QAPs that support clinically-important AMR Mgen testing as cross-platform IVD quality controls, validation, verification, and training panels, and as external quality assessment samples. Reported Earnings • May 12
Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0.005 in 2Q 2022) Second quarter 2023 results: EPS: CA$0 (down from CA$0.005 in 2Q 2022). Revenue: CA$4.22m (down 14% from 2Q 2022). Net income: CA$31.6k (down 96% from 2Q 2022). Profit margin: 0.7% (down from 15% in 2Q 2022). Revenue is forecast to grow 53% p.a. on average during the next 2 years, compared to a 66% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 10
First quarter 2023 earnings: Revenues miss analyst expectations First quarter 2023 results: Revenue: CA$2.50m (down 49% from 1Q 2022). Net loss: CA$1.30m (down 248% from profit in 1Q 2022). Revenue missed analyst estimates by 35%. Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 74% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jan 31
Microbix Biosystems Inc. Launches QAP to Support "Monkeypox" Testing Microbix Biosystems Inc. announced that it is launching a new quality assessment product ("QAPTM") to support molecular diagnostic ("MDx") testing for the Non-Variola Orthopoxvirus ("Mpox"), the cause of the cutaneous infection colloquially-known as "Monkeypox." From traditional low-level incidence in Central and Western Africa, incidence of Mpox surged meaningfully within many countries in 2022, leading to increased testing for this virus. However, transmission of this virus currently requires close or prolonged contact between individuals, limiting its pandemic potential. Microbix chose to create a QAP to support Mpox testing following requests from its customers that provide proficiency-testing and accreditation services to clinical laboratories (i.e., "PT" or "EQA" providers) and to prepare for the inclusion of Mpox in standard worldwide genital ulcer disease diagnostic programs. Although the frequency of testing for Mpox is currently limited, labs must become and remain accredited for such testing by PT/EQA providers. Microbix will be providing Mpox QAPs in liquid or FLOQSwab® formats for that PT/EQA need and as a result, its sales are not expected to be correlated to the rates of Mpox infection or with how much this virus is the subject of news media coverage. In otherwise healthy persons, Mpox infection is usually self-limiting and non-fatal in nature. However, Mpox viral DNA has been detected in human blood, which raises the question of whether blood-borne transmission is a possibility with this emerging pathogen. If blood-borne transmission of Mpox is proven at any future time, the need for routine screening of blood and blood products could arise. In collaboration with its PT/EQA partners, the Microbix Mpox QAP has now been validated for use across 11 leading MDx testing systems and multiple Lab Developed Tests, at 33 clinical laboratories in multiple European and Scandinavian nations. The Mpox QAP validation results may be presented by Microbix or its collaborators at a future scientific conference, in accordance with industry practices and standards. PT/EQA shipments of the Mpox QAP can now commence and Microbix expects material sales of this product starting in its current fiscal year. Tillkännagivande • Jan 20
Microbix Biosystems Inc., Annual General Meeting, Mar 29, 2023 Microbix Biosystems Inc., Annual General Meeting, Mar 29, 2023. Reported Earnings • Dec 22
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CA$0.013 (down from CA$0.028 in FY 2021). Revenue: CA$19.1m (up 2.6% from FY 2021). Net income: CA$1.79m (down 45% from FY 2021). Profit margin: 9.4% (down from 17% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.4%. Earnings per share (EPS) also missed analyst estimates by 35%. Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 71% growth forecast for the Biotechs industry in Canada. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 16
Price target decreased to CA$1.13 Down from CA$1.50, the current price target is an average from 2 analysts. New target price is 134% above last closing price of CA$0.48. Stock is down 31% over the past year. The company is forecast to post earnings per share of CA$0.02 for next year compared to CA$0.028 last year. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Director Jennifer Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 07
Microbix Biosystems Inc. Presenting Test-Workflow Validation Results At EMMD Microbix Biosystems Inc. will present results of novel methods to support diagnostic accuracy and whole-process workflow validation of cervical cancer screening tests on self-collected patient specimens. The poster presentation will be made at the 12th European Meeting on Molecular Diagnostics (“EMMD”) taking place in Noordwijk, Netherlands from October 12 to 14, 2022. Ample evidence supports use of self-collected vaginal samples to improve participation in cervical cancer screening programs based on molecular (“MDx”) detection of Human Papilloma Virus (“HPV”). However, broad adoption of self-collection has been set-back by a lack of materials and methods to evaluate the whole workflow experienced by a specimen – from collection to final diagnostic result. This critical gap is bridged by the current study using Microbix PROCEEDx™FLOQ® simulated positive HPV samples eluted into Copan MSwab® medium – evaluating whether HPV was effectively eluted from the simulated self-collected swabs and then detected by commercial in vitro diagnostic (“IVD”) PCR-based MDx assays. The study determined that three positive specimens simulating infection with high-risk HPV types (16, 18 & 45) and a negative sample were detected and individually identified on six IVD MDx assays: the Abbott Alinity m HPV & Abbott Realtime HPV, Qiagen NeumoDx HPV, Roche cobas 4800 HPV & Roche cobas 6800 HPV, and Seegene Anyplex II HPV28. Accuracy was 100% across all sample types and assays. The poster will be available on Microbix’s website (https://microbix.com) and from EMMD after its presentation. HPV represents a family of over 100 virus sub-types, of which 14 are deemed “high-risk” as they are proven to directly cause cancers, including but not limited to cervical cancer. Most sexually-active adults become infected with one or more types of HPV and such infections can be persistent. MDx tests permit early detection and guide timely preventative healthcare by identifying those at-risk years before the development of cancers. However, MDx-based screening programs require rigorous workflow design and ongoing validation to ensure their accuracy. Many healthcare systems now plan to resume the roll-out of MDx-based HPV screening programs that were delayed as a result of the COVID-19 pandemic, important diagnostic healthcare advancements that Microbix is pleased to support with its products and services. Empowering women to collect vaginal samples in private, safe, and convenient locations is expected to promote patient access to healthcare and accelerate the widespread adoption of MDx-based HPV and cervical cancer screening programs. Microbix is proud to be a strategic partner of Copan and help to accelerate the evolution to self-collection by offering HPV-oriented “PROCEED™FLOQ®” (RUO) and prospective “REDx™FLOQ®” (IVD) quality assessment products (QAPs™) worldwide. Purchase enquiries for Microbix’s QAPs can be e-mailed to customer.service@microbix.com. Recent Insider Transactions • Sep 13
President recently sold CA$70k worth of stock On the 7th of September, Cameron Groome sold around 140k shares on-market at roughly CA$0.50 per share. This transaction amounted to 4.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Cameron has been a net seller over the last 12 months, reducing personal holdings by CA$151k. Recent Insider Transactions Derivative • Aug 24
President exercised options to buy CA$191k worth of stock. On the 17th of August, Cameron Groome exercised options to buy 375k shares at a strike price of around CA$0.28, costing a total of CA$105k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since December 2021, Cameron's direct individual holding has increased from 1.69m shares to 2.69m. Company insiders have collectively bought CA$515k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Aug 12
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: EPS: CA$0.005 (down from CA$0.013 in 3Q 2021). Revenue: CA$5.01m (down 8.1% from 3Q 2021). Net income: CA$638.5k (down 58% from 3Q 2021). Profit margin: 13% (down from 28% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 7.9%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 28%, compared to a 2,709% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Aug 11
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from CA$0.03 to CA$0.02 per share. Revenue forecast steady at CA$21.8m. Net income forecast to grow 9.9% next year vs 44% decline forecast for Biotechs industry in Canada. Consensus price target of CA$1.13 unchanged from last update. Share price was steady at CA$0.52 over the past week. Recent Insider Transactions Derivative • Jul 27
President exercised options to buy CA$182k worth of stock. On the 20th of July, Cameron Groome exercised options to buy 375k shares at a strike price of around CA$0.28, costing a total of CA$105k. This transaction amounted to 16% of their direct individual holding at the time of the trade. Since December 2021, Cameron's direct individual holding has increased from 1.69m shares to 2.38m. Company insiders have collectively bought CA$410k more than they sold, via options and on-market transactions, in the last 12 months. Tillkännagivande • Jun 04
Microbix Biosystems Inc. Presenting Test Validation Methods at AACC Microbix Biosystems Inc. announced it is presenting about the utility of its Quality Assessment Products ("QAPsTM") to monitor the end-to-end diagnostic process, including the impact of "preanalytical" sample-handling variables on test accuracy, at the 2022 "Preanalytical Phase Conference" of the American Association of Clinical Chemistry ("AACC") taking place in Alexandria, Virginia from June 3-4, 2022. Microbix is attending this AACC conference to present about these important aspects of infectious disease testing, alongside leaders in the global medical diagnostics industry. Microbix will also be conducting business development activities in relation to its expanding portfolio of QAPs, which includes Health Canada, U.S. FDA, EU "CE mark," or TGA (Australia) in-vitro-diagnostic ("IVD") regulated SKUs and research-use-only ("RUO") designated SKUs across both liquid-vial and Copan FLOQSwab® formats. Its poster presentation is titled "Simulated Swab Specimens for Whole Workflow Quality Control of SARS-CoV-2 Molecular Diagnostic Testing." The poster details methods of using Microbix's REDxTMFLOQ® SARS-CoV-2 Swab Positive Control QAPs to assess the influence on patient-samples of hold-period durations of up to five (5) days, high temperatures of 35-40 °C, or a freeze-thaw cycle, relative to more optimal conditions. The study examined the effects of such conditions on the detectability of Microbix's positive QAPs at full-strength and in 1:100 diluted form relative to strong-positive and weak-positive clinical specimens, using two different viral transport mediums (Microbix's DxTMTM branded viral transport medium and another commercially-available brand) and two different Health Canada approved assays. The results establish that the effects of sample storage and handling conditions can be accurately modeled using QAPs as proxies for clinical patient-samples. These Microbix products and methods can be used to validate processes for new-generation testing practices, such as at-home sample-collection, for a wide range of disease screening and diagnostic purposes, including COVID-19 and high-risk HPV infection, among others. The study was conducted in collaboration with FH Health Laboratory of Toronto, Ontario, whose support in sourcing clinical specimens, testing, and tabulation is gratefully acknowledged. Major Estimate Revision • May 19
Consensus EPS estimates fall by 28% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CA$23.1m to CA$20.9m. EPS estimate also fell from CA$0.04 per share to CA$0.03 per share. Net income forecast to grow 16% next year vs 49% decline forecast for Biotechs industry in Canada. Consensus price target down from CA$1.50 to CA$1.25. Share price rose 11% to CA$0.51 over the past week. Reported Earnings • May 13
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: EPS: CA$0.005 (down from CA$0.007 in 2Q 2021). Revenue: CA$4.88m (up 12% from 2Q 2021). Net income: CA$733.5k (down 9.2% from 2Q 2021). Profit margin: 15% (down from 19% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 58%. Over the next year, revenue is forecast to grow 13% compared to a 4.9% decline forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Tillkännagivande • May 13
Microbix Biosystems Inc. Provides Earnings Guidance for the Fiscal Year 2022 Microbix Biosystems Inc. provided earnings guidance for the fiscal year 2022. For the year, the company excepts that fiscal 2022 will realize materially-positive net earnings, as were achieved in fiscal 2021. Tillkännagivande • May 02
Microbix Biosystems Inc. to Present Performance Results of its Quality Assessment Product at the 2022 Clinical Virology Symposium of the American Society for Microbiology Microbix Biosystems Inc. (Microbix®) announced that it will present performance results of its Quality Assessment Products (‘QAPs™’) supporting molecular-diagnostic tests for the Omicron variant of the SARS-CoV-2 virus (‘Omicron’) at the 2022 Clinical Virology Symposium of the American Society for Microbiology (‘CVS’) taking place in West Palm Beach, Florida from May 1-4, 2022.At CVS, Microbix will be exhibiting alongside leading diagnostics firms that provide tests for detection of COVID and other infectious diseases. Microbix will also review performance of its QAPs to support quality management of testing for infection with Omicron (the B.1.1.529 variant of SARS-CoV-2). With over 50 reported mutations in its viral genome, Omicron can lead to reduced assay sensitivity or the outright inability of assays to detect it. Use of Microbix’s REDxFLOQ or PROCEEDxFLOQ QAPs offer whole-genome controls that contain all Omicron mutations and provide lot-to-lot consistency in order to optimally support clinical laboratories and test-makers in monitoring their assay performance. Microbix now has QAPs to support tests for six (6) variants of the virus that causes COVID available for sale in Canada, Europe, the United States, and other commercially-important jurisdictions under its ‘REDx™’ or ‘PROCEEDx™’ brand names. Its QAPs support tests for the ‘Wuhan’ strain, as well as those variants that have since become most prevalent, including the Alpha (B.1.1.7 or UK), Beta (B.1.351 or South African), Delta (B.1.617 or Indian), Gamma (P.1 or Brazilian), and Omicron (B.1.1.529 or Botswana). Microbix is proud to be a strategic partner of Copan and offer a broad portfolio of infectious-disease oriented ‘PROCEED™FLOQ®’ (RUO) and ‘REDx™FLOQ®’ (IVD) QAPs to support testing programs worldwide. Price Target Changed • Apr 27
Price target decreased to CA$1.50 Down from CA$1.70, the current price target is provided by 1 analyst. New target price is 188% above last closing price of CA$0.52. Stock is down 21% over the past year. The company is forecast to post earnings per share of CA$0.036 for next year compared to CA$0.028 last year. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Director Jennifer Stewart was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • Apr 20
President exercised options to buy CA$206k worth of stock. On the 13th of April, Cameron Groome exercised options to buy 375k shares at a strike price of around CA$0.28, costing a total of CA$105k. This transaction amounted to 19% of their direct individual holding at the time of the trade. Since June 2021, Cameron's direct individual holding has increased from 1.54m shares to 2.00m. Company insiders have collectively bought CA$376k more than they sold, via options and on-market transactions, in the last 12 months. Tillkännagivande • Apr 09
Microbix Biosystems Inc. Presents HPV Product Results at EUROGIN Microbix Biosystems Inc. announced that it will present performance results of its Quality Assessment Products (QAPs) supporting Human Papillomavirus (HPV) molecular-diagnostic screening-tests at the 2022 annual congress of the European Research Organization on Genital Infection and Neoplasia (“EUROGIN”) taking place in Düsseldorf, Germany from April 10-12, 2022. At EUROGIN, Microbix will be exhibiting alongside leading diagnostics firms that provide screening-tests for detection of HPV infections. Microbix has QAPs to support tests for eight (8) high-risk HPV types available for sale in Canada, Europe, the United States, and other commercially-important jurisdictions under its “REDx™ Controls” or “PROCEEDx™” brand names. Most sexually-active adults become infected with one or more types of HPV and its high-risk types are well-known and common causes of human cancers. Tests to detect infection with high-risk HPV provide important preventative health information and require validated, regulated, and third-party test-controls to help ensure their accuracy. Microbix will also review performance of its multiplex high-risk HPV QAPs in supporting quality management of testing for high-risk types of HPV via full and extended genotyping assays. Its poster presentation is titled “Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel.” The poster details the performance of multiplex high-risk HPV QAPs in supporting BD Onclarity™ assays and Microbix gratefully acknowledges the assistance of Becton Dickinson Life Sciences in planning and executing these evaluations. Major Estimate Revision • Feb 13
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from CA$0.04 to CA$0.04 per share. Revenue forecast steady at CA$22.6m. Net income forecast to grow 64% next year vs 12% decline forecast for Biotechs industry in Canada. Consensus price target down from CA$1.70 to CA$1.50. Share price rose 6.5% to CA$0.66 over the past week. Reported Earnings • Feb 12
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CA$0.007 (up from CA$0.001 in 1Q 2021). Revenue: CA$4.86m (up 54% from 1Q 2021). Net income: CA$880.8k (up CA$750.0k from 1Q 2021). Profit margin: 18% (up from 4.1% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 40%. Over the next year, revenue is forecast to grow 14%, compared to a 5,060% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Price Target Changed • Feb 11
Price target decreased to CA$1.50 Down from CA$1.80, the current price target is provided by 1 analyst. New target price is 121% above last closing price of CA$0.68. Stock is up 11% over the past year. The company is forecast to post earnings per share of CA$0.04 for next year compared to CA$0.028 last year. Tillkännagivande • Feb 02
Microbix Biosystems Inc. Launches Omicron Variant Test Control Microbix Biosystems Inc. announced the expansion of its portfolio of Quality Assessment Products (“QAPs™”) to include a swab-formatted control that helps validate the accuracy and integrity of the workflows of nucleic-acid based tests (e.g., “PCR” tests) for SARS-CoV-2 (“COVID”) Wuhan strain and the Omicron variant (“Omicron”) – the latter now being the most prevalent form of COVID. Specifically, Microbix is commercializing its In-Vitro Diagnostic (“IVD”) quality control to support workflow accuracy of clinical laboratory PCR tests that aim to detect and differentiate SARS-CoV-2 Wuhan strain and Omicron infections. This innovative, proprietary, and branded control provides a fully-compliant, comprehensive, and cost-effective quality management tool to help avoid the systemic errors that can be driven by technicians, consumables, or instruments. Users of this IVD control will include lab accreditation agencies, makers of tests oriented to clinical labs or point-of-care, and clinical labs or medical clinics. This Microbix Omicron QAP is made using Copan® FLOQSwabs® – the optimal format for accuracy and point-of-care use, and with room-temperature stability for 12 months. As for all Microbix’s QAPs, this latest IVD control contains all possible PCR targets and is validated on multiple test platforms. This new QAPs SKU is labelled REDx™FLOQ® SARS-CoV-2 B.1.1.529 SWAB POSITIVE CONTROL and is now available to support clinical laboratory quality management systems (“QMS”) covering central lab and point-of care workflows in both the U.S. and Canada. Research-Use-Only (“RUO”) PROCEEDx™FLOQ® versions are now available for other markets, with REDx® IVD versions to follow. Microbix’s QAPs portfolio now consists of over 70 proprietary SKUs in the categories of respiratory, sexually-transmitted, and gastrointestinal infectious diseases. Of that portfolio, 17 QAPs are available as REDx Controls for IVD use by clinical labs. In addition to QAPs to support PCR-based testing for the most important respiratory illnesses, including all major COVID variants, Microbix also has IVD QAPs to support antigen-based respiratory pathogen tests (e.g., REDxFLOQ SARS-CoV-2 Ag). Microbix’s QAPs for PCR-test and Antigen-test support are also available as ONBOARDx™ kits that include both positive and negative controls for convenient qualification of new instruments for clinical use and for the training of laboratory staff. This portfolio of QAPs is in widespread use and can be paired with Microbix’s DxTM™ viral transport medium to enable collection and stabilization of patient test-sample specimens. Recent Insider Transactions Derivative • Jan 16
President exercised options to buy CA$274k worth of stock. On the 11th of January, Cameron Groome exercised options to buy 375k shares at a strike price of around CA$0.28, costing a total of CA$105k. This transaction amounted to 22% of their direct individual holding at the time of the trade. Since March 2021, Cameron's direct individual holding has increased from 1.41m shares to 1.69m. Company insiders have collectively bought CA$907k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Dec 25
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CA$0.028 (up from CA$0.059 loss in FY 2020). Revenue: CA$18.6m (up 77% from FY 2020). Net income: CA$3.23m (up CA$9.46m from FY 2020). Profit margin: 17% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 36%, compared to a 4,974% growth forecast for the pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 58% per year whereas the company’s share price has increased by 63% per year. Tillkännagivande • Dec 21
Microbix Biosystems Inc. Launches Multiplex Respiratory PCR-Test Control Microbix Biosystems Inc. announced the expansion of its portfolio of Quality Assessment Products (“QAPs™”) to include single-unit swab-formatted controls that simultaneously support PCR tests for SARS-CoV-2 (“COVID”), Influenza A (“Flu A”), Influenza B (“Flu B”), and Respiratory Syncytial Virus (“RSV”), four of the most-common causes of viral infectious respiratory illness globally. Specifically, Microbix is commercializing In-Vitro Diagnostic (“IVD”) quality controls to support workflow accuracy of “multiplex” clinical laboratory PCR tests that detect COVID, Flu A, Flu B, and RSV from a single patient-sample. These innovative, proprietary, and branded controls provide a fully-compliant, comprehensive, and cost-effective quality management tool to help avoid the systemic errors that can be driven by technicians, consumables, or instruments. Users of this IVD control will include lab accreditation agencies, makers of tests oriented to clinical labs or point-of-care, and clinical labs or medical clinics. This Microbix multiplex QAP is made using Copan® FLOQSwabs® – the optimal format for accuracy and point-of-care use, with room-temperature stability for 12 months. As for all Microbix’s QAPs, this latest IVD control contains all possible PCR targets and is validated on multiple test platforms. This new QAPs SKU is branded REDx™FLOQ® SARS-CoV-2/Flu A&B/RSV Swab Positive Control and is now available to support clinical laboratory quality management systems (“QMS”) covering central lab and point-of care workflows in both the U.S. and Canada. Research-Use-Only (“RUO”) PROCEEDx®FLOQ® versions are now available for other markets, with REDx IVD versions to follow. Microbix’s QAPs portfolio now consists of over 70 proprietary SKUs in the categories of respiratory, sexually-transmitted, and gastrointestinal infectious diseases. Of that portfolio, 16 QAPs are available as REDx™ Controls for IVD use by clinical labs. In addition to QAPs to support PCR-based testing for each of these important respiratory illnesses, Microbix also has IVD QAPs to support antigen-based respiratory pathogen tests (e.g., REDxFLOQ SARS-CoV-2 Ag). Microbix’s QAPs for PCR-test and Antigen-test support are also available as ONBOARDx™ kits that include both positive and negative controls for convenient qualification of new instruments for clinical use and for the training of laboratory staff. This portfolio of COVID-oriented QAPs is in widespread use and can be paired with Microbix’s DxTM™ viral transport medium to enable collection and stabilization of patient test-sample specimens. Board Change • Dec 06
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Independent Director Anthony Giovinazzo was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Nov 27
Chief Financial Officer recently sold CA$68k worth of stock On the 25th of November, James Currie sold around 100k shares on-market at roughly CA$0.68 per share. This was the largest sale by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.